List view / Grid view
30 June 2014 | By Merck
Merck announced the European Medicines Agency has accepted for review a Marketing Authorization Application for pembrolizumab (MK-3475)...
30 June 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces that it has entered into an exclusive license agreement with TTFactor S.r.l...
27 June 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve the use of Avastin® (bevacizumab)...
27 June 2014 | By Pfizer
The board of directors of Pfizer Inc. declared a 26-cent third-quarter 2014 dividend on the company’s common stock...
27 June 2014 | By Gilead
If approved, sofosbuvir would be the first all-oral treatment regimen for patients in Japan with genotype 2 HCV...
26 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™)...
26 June 2014 | By AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration Oncologic Drugs Advisory Committee voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib...
26 June 2014 | By AbbVie
AbbVie announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888)...
26 June 2014 | By Janssen Pharmaceutica
New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide...
25 June 2014 | By kdm communications
Tecan has introduced the Fluent™ laboratory automation solution, the latest addition to its world-class laboratory automation portfolio...
25 June 2014 | By Merck
If approved, fixed-dose combination would be used with other antiretroviral agents for the treatment of HIV-1 in adults, adolescents and certain pediatric patients...
25 June 2014 | By Johnson & Johnson
Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc. announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute...
25 June 2014 | By Merck
Merck announced the future appointment of Michael J. Holston as general counsel, effective July 01, 2015...
25 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma was stopped early...
24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
